GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

The Australian government announces Olaparib now available on the PBS for HER2-negative metastatic breast cancer patients with mutated BRCA1 or BRCA2 gene. As part of the PBS listing, the Government ...

Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

At six years, 79.6% of olaparib-treated patients remained free of invasive recurrence and 83.5% remained free of distant recurrence, compared to 70.3% and 75.7%, respectively, in the placebo group.

Nuformix plc (LON:NFX – Get Free Report)’s share price was down 10% on Monday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 1,986,748 shares were ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

These data reinforce the importance of germline BRCA testing at the time of diagnosis, so we can identify all eligible patients who may benefit from treatment with olaparib as early as possible." ...

INR:6816. bubble slots AstraZeneca and Merck jointly announced that the PARP inhibitor Olaparib is expected to be approved by the end of the year Chinese data releas ...